C
Collin M. Blakely
Researcher at University of California, San Francisco
Publications - 97
Citations - 4742
Collin M. Blakely is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 26, co-authored 81 publications receiving 3196 citations. Previous affiliations of Collin M. Blakely include University of Texas Southwestern Medical Center & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele,Alexander Drilon,Alexander Drilon,Luis Paz-Ares,Salvatore Siena,Alice T. Shaw,Anna F. Farago,Collin M. Blakely,Takashi Seto,Byung Chul Cho,D. Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido-Laguna,Stephen V. Liu,Paul Conkling,Thomas John,Marwan Fakih,Darren Sigal,Herbert H. Loong,Gary L Buchschacher,Pilar Garrido,Jorge Nieva,Conor E. Steuer,Tobias Overbeck,Daniel W. Bowles,Elizabeth Fox,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann M. Johnson,Susan Eng,Timothy R. Wilson,George D. Demetri +38 more
TL;DR: Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.
Journal ArticleDOI
Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation
Michael Gale,Collin M. Blakely,Bart Kwieciszewski,Seng Lai Tan,Michelle L. Dossett,Norina M. Tang,Marcus J. Korth,Stephen J. Polyak,David R. Gretch,Michael G. Katze +9 more
TL;DR: Results indicate that mutations within the PKR-binding region of NS5A, including those within the ISDR, can disrupt the NS5a-PKR interaction, possibly rendering HCV sensitive to the antiviral effects of interferon.
Journal ArticleDOI
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely,Thomas B.K. Watkins,Wei Wu,Beatrice Gini,Jacob J. Chabon,Caroline E. McCoach,Nicholas McGranahan,Gareth A. Wilson,Nicolai Juul Birkbak,Victor Olivas,Julia K Rotow,Ashley Maynard,Victoria E. Wang,Matthew A. Gubens,Kimberly C. Banks,Richard B. Lanman,Aleah F. Caulin,John St. John,Anibal Cordero,Petros Giannikopoulos,Andrew Simmons,Philip C. Mack,David R. Gandara,Hatim Husain,Robert C. Doebele,Jonathan W. Riess,Maximilian Diehn,Charles Swanton,Trever G. Bivona +28 more
TL;DR: This study calls for revisiting the prevailing single-gene driver-oncogene view and links clinical outcomes to co-occurring genetic alterations in patients with advanced-stage EGFR-mutant lung cancer.
Journal ArticleDOI
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Ashley Maynard,Caroline E. McCoach,Julia K Rotow,Lincoln Harris,Franziska Haderk,D. Lucas Kerr,Elizabeth A. Yu,Erin L. Schenk,Weilun Tan,Alexander Zee,Michelle Tan,Philippe Gui,Tasha Lea,Wei Wu,Anatoly Urisman,Kirk D. Jones,Rene Sit,Pallav K. Kolli,Eric J. Seeley,Yaron Gesthalter,Daniel D. Le,Kevin A. Yamauchi,David M. Naeger,David M. Naeger,Sourav Bandyopadhyay,Khyati N. Shah,Lauren Cech,Nicholas J. Thomas,Anshal Gupta,Mayra Gonzalez,Hien Do,Lisa Tan,Bianca Bacaltos,Rafael Gomez-Sjoberg,Matthew A. Gubens,Thierry Jahan,Johannes R. Kratz,David M. Jablons,Norma Neff,Robert C. Doebele,Jonathan S. Weissman,Collin M. Blakely,Spyros Darmanis,Trever G. Bivona +43 more
TL;DR: How therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes is highlighted, with scRNA-seq illuminating targetable oncogenes beyond those detected clinically.
Journal ArticleDOI
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Robert J. Nichols,Franziska Haderk,Carlos Stahlhut,Christopher J. Schulze,Golzar Hemmati,David Wildes,Christos Tzitzilonis,Kasia Mordec,Abby Marquez,Jason Romero,Tientien Hsieh,Aubhishek Zaman,Victor Olivas,Caroline E. McCoach,Collin M. Blakely,Zhengping Wang,Gert Kiss,Elena S. Koltun,Adrian Liam Gill,Mallika Singh,Mark A. Goldsmith,Jacqueline Smith,Trever G. Bivona +22 more
TL;DR: It is shown that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-molecule allosteric inhibitor, is effective in human cancer models bearing RAS–GTP-dependent oncogenic BRAF, NF1 loss or nucleotide-cycling oncogenesis RAS.